Bleomycin, actinomycin-D, and cisplatin treatment of ovarian germ-cell malignancies contributes to reducing adverse drug reactions

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1235-1238

  Sumi, Toshiyuki ^a   Ishiko, Osamu ^a   Yoshida, Hiroyuki ^a   Ogita, Sachio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Actinomycin D; Adverse drug reaction (ADR); BAP; BEP; Bleomycin; Chemotherapy; Cisplatin; Ovarian germ cell tumor

Indexed keywords

ANTINEOPLASTIC AGENT; BAP PROTOCOL 2; BEP PROTOCOL; BLEOMYCIN; CISPLATIN; DACTINOMYCIN; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GERM CELL TUMOR; HUMAN; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CISPLATIN; DACTINOMYCIN; ETOPOSIDE; FEMALE; GERMINOMA; HUMANS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0034323586     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1235     Document Type: Article

References (22)

1. Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J and Sleijfer DT: Intraperitoneal human recombinant Interferon alpha-2b in minimal residual ovarian cancer. Eur J Cancer 26: 353-358, 1990.
2. Scully RE: Tumors of the Ovary and Maldeveloped Gonads. Fascicle 16. Armed Forces Institute of Pathology, Washington, DC, 1979.
3. Berek JS and Hacker NF: Ovarian and fallopian tubes. In: Cancer Treatment. Haskell CM (ed.). 4th edition. WB Saunders, Philadelphia, 1995.
4. Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, Hacker N and Friedlander ML: Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol 12: 378-384, 1994.
5. Williams S, Blessing JA, Liao SY, Ball H and Hanjani P: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 12: 701-704, 1994.
6. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A and Kohler MF: Malignant germ cell tumors of ovary. Obstet Gynecol 95: 128-133, 2000.
7. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N and Mangioni C: Surgical management ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 86: 367-372, 1995.
8. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO and Rorth M: Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumors. Lancet 338: 359-363, 1991.
9. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schoffski P, Kuczyk M, Schmoll HJ, Kanz L and Bokemeyer C: Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16: 3386-3391, 1998.
10. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
11. Mantel N: Evaluation of survival data and two new ranks order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
12. Kurman RJ and Norris HJ: Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol 48: 579-589, 1976.
13. Norris HJ, Zirkin HJ and Benson WL: Immature malignant teratoma of the ovary. Cancer 37: 2359-2372, 1976.
14. Kurman RJ and Norris HJ: Endodermal sinus tumor of the ovary. A clinical and pathologic analysis of 71 cases. Cancer 38: 2404-2419, 1976.
15. Gershenson DM: Update on malignant ovarian germ cell tumors. Cancer 71: 1581-1590, 1993.
16. Smith JP and Rutledge F: Advances in chemotherapy for gynecologic cancer. Cancer 36: 669-674, 1975.
17. Einhorn LH and Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293-298,1977.
18. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA and Loehrer PJ: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435-1440, 1987.
19. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG and Wharton JT: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8: 715-720, 1990.
20. Saxman SB, Finch D, Gonin R and Einhorn LH: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 16: 702-706, 1998.
21. Jakob A, Kollmannsberger C, Kanz L and Bokemeyer C: Late toxicity after chemotherapy of malignant testicular tumors. Urologe A 37: 635-647, 1998.
22. De Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S and Schornagel J: Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 17: 831-833, 1999.